MGNX Stock Overview
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.01|
|52 Week High||US$29.16|
|52 Week Low||US$2.13|
|1 Month Change||-14.00%|
|3 Month Change||-66.03%|
|1 Year Change||-88.73%|
|3 Year Change||-82.06%|
|5 Year Change||-83.05%|
|Change since IPO||-87.96%|
Recent News & Updates
The Consensus EPS Estimates For MacroGenics, Inc. (NASDAQ:MGNX) Just Fell Dramatically
The analysts covering MacroGenics, Inc. ( NASDAQ:MGNX ) delivered a dose of negativity to shareholders today, by making...
|MGNX||US Biotechs||US Market|
Return vs Industry: MGNX underperformed the US Biotechs industry which returned -24.5% over the past year.
Return vs Market: MGNX underperformed the US Market which returned -18.8% over the past year.
|MGNX Average Weekly Movement||15.4%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.0%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: MGNX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: MGNX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies.
MacroGenics Fundamentals Summary
|MGNX fundamental statistics|
Is MGNX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MGNX income statement (TTM)|
|Cost of Revenue||US$225.58m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.54|
|Net Profit Margin||-303.19%|
How did MGNX perform over the long term?See historical performance and comparison
Is MGNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MGNX?
Other financial metrics that can be useful for relative valuation.
|What is MGNX's n/a Ratio?|
Price to Sales Ratio vs Peers
How does MGNX's PS Ratio compare to its peers?
|MGNX PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
STRO Sutro Biopharma
FDMT 4D Molecular Therapeutics
LCTX Lineage Cell Therapeutics
RIGL Rigel Pharmaceuticals
Price-To-Sales vs Peers: MGNX is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (11.7x).
Price to Earnings Ratio vs Industry
How does MGNX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: MGNX is good value based on its Price-To-Sales Ratio (2.6x) compared to the US Biotechs industry average (13.7x)
Price to Sales Ratio vs Fair Ratio
What is MGNX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.6x|
|Fair PS Ratio||0.2x|
Price-To-Sales vs Fair Ratio: MGNX is expensive based on its Price-To-Sales Ratio (2.6x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).
Share Price vs Fair Value
What is the Fair Price of MGNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate MGNX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate MGNX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MGNX's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is MacroGenics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MGNX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MGNX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MGNX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MGNX's revenue (15.1% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: MGNX's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MGNX is forecast to be unprofitable in 3 years.
Discover growth companies
How has MacroGenics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MGNX is currently unprofitable.
Growing Profit Margin: MGNX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MGNX is unprofitable, and losses have increased over the past 5 years at a rate of 17.1% per year.
Accelerating Growth: Unable to compare MGNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: MGNX has a negative Return on Equity (-121.92%), as it is currently unprofitable.
Discover strong past performing companies
How is MacroGenics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: MGNX's short term assets ($218.2M) exceed its short term liabilities ($67.1M).
Long Term Liabilities: MGNX's short term assets ($218.2M) exceed its long term liabilities ($26.1M).
Debt to Equity History and Analysis
Debt Level: MGNX is debt free.
Reducing Debt: MGNX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MGNX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MGNX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 13.6% each year
Discover healthy companies
What is MacroGenics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MGNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MGNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MGNX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MGNX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as MGNX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Koenig (69 yo)
Dr. Scott Koenig, M.D., Ph D., has been the President and Chief Executive Officer of Macrogenics, Inc. since September 2001. Dr. Koenig is Co-Founder of Macrogenics.He served as Senior Vice President of R...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD4.87M) is above average for companies of similar size in the US market ($USD1.75M).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
Experienced Management: MGNX's management team is seasoned and experienced (5.4 years average tenure).
Experienced Board: MGNX's board of directors are considered experienced (5.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MGNX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.
MacroGenics, Inc.'s employee growth, exchange listings and data sources
- Name: MacroGenics, Inc.
- Ticker: MGNX
- Exchange: NasdaqGS
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$198.721m
- Shares outstanding: 61.33m
- Website: https://www.macrogenics.com
Number of Employees
- MacroGenics, Inc.
- 9704 Medical Center Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.